Year-end Report January - December 2011

February 16, 2012 08:30 (CET)

· Laquinimod - a clinical trial is planned prior to filing an NDA in the US
                    
· TASQ         - an investigator-sponsored Phase I clinical trial launched
                    - enrolment of patients for Phase III trial proceeding according to plan
 
· ANYARA    - Phase III trial continuing according to plan

· 57-57          - a clinical trial in systemic sclerosis/scleroderma initiated

· ISI              - project is proceeding as planned

· RhuDex®    - a Phase I clinical formulation study launched

· Focusing of the operation; notice of termination of employment to 25 staff members

· Net sales SEK 234.6 M (11.4)

· Operating loss SEK 100.9 M (Loss: 229.0)

· Loss after tax SEK 94,5 M (Loss: 221.1)

· Loss per share for the period was SEK 1.38 (Loss: 3.38)
 

For further information, please contact:

Tomas Leanderson
President and CEO
Tel +46 (0)46-19 20 95    

Hans Kolam     
CFO     
Tel +46 (0)46-19 20 44     

Active Biotech AB (Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel +46 (0)46-19 20 00 
Fax +46 (0)46-19 11 00

This report is also available at www.activebiotech.com   

Year-end Report January - December 2011